Grant: Master's Award: Canada Graduate Scholarships
McGill University
$17,500.00
Effectiveness of antiretroviral therapy in women living with HIV: are all antiretroviral classes equivalent?
EF 2022-23
Résumé
People living with HIV (PLHIV) can now lead healthy lives thanks to antiretroviral therapy (ART). Successful ART treatment is able to reduce the amount of virus in the blood to such low levels that we consider them undetectable. However, women living with HIV (WLWH) experience greater difficulties with committing to ART due to unique social factors and challenges. ART consists of taking three drugs: two of them being from the same drug type, and the third drug being different. The third drug can be chosen from three drug classes, but a specific drug class, termed integrase strand transfer inhibitor (INSTI) has been shown to be more effective in lowering HIV with the least side effects. Additionally, the recommended 95% adherence target can be difficult to meet and ultimately discouraging as it is a near perfect level of commitment to ART. Whether this 95% target is essential with INSTI drug class is unclear. Using the Canadian HIV Women’s Sexual and Reproductive Health Cohort Study, I plan to describe the change of ART among WLWH in Quebec, Ontario and British Columbia over 3 years, and measure the level of adherence to ART linked with lower levels of HIV in the blood. I will also measure the association between the third drug class and success in lowering HIV levels in the blood among PLHIV using data from the Quebec HIV cohort. This information will provide care that is based on current information and can be better adapted to the needs and realities of PLHIV.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
485955
Name
Mokaddam Maysaloun
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Effectiveness of antiretroviral therapy in women living with HIV: are all antiretroviral classes equivalent?
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Antiretroviral Therapy; Hiv; Integrase Strand Transfer Inhibitor; People Living With Hiv; Women Living With Hiv
Abstract
People living with HIV (PLHIV) can now lead healthy lives thanks to antiretroviral therapy (ART). Successful ART treatment is able to reduce the amount of virus in the blood to such low levels that we consider them undetectable. However, women living with HIV (WLWH) experience greater difficulties with committing to ART due to unique social factors and challenges. ART consists of taking three drugs: two of them being from the same drug type, and the third drug being different. The third drug can be chosen from three drug classes, but a specific drug class, termed integrase strand transfer inhibitor (INSTI) has been shown to be more effective in lowering HIV with the least side effects. Additionally, the recommended 95% adherence target can be difficult to meet and ultimately discouraging as it is a near perfect level of commitment to ART. Whether this 95% target is essential with INSTI drug class is unclear. Using the Canadian HIV Women’s Sexual and Reproductive Health Cohort Study, I plan to describe the change of ART among WLWH in Quebec, Ontario and British Columbia over 3 years, and measure the level of adherence to ART linked with lower levels of HIV in the blood. I will also measure the association between the third drug class and success in lowering HIV levels in the blood among PLHIV using data from the Quebec HIV cohort. This information will provide care that is based on current information and can be better adapted to the needs and realities of PLHIV.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Mokaddam, Maysaloun
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~